Discover
BIVI
BioVie Inc.
2.01
1 x 1.59
1 x 2.63
bid
ask
-
0.17
7.80%
12:12 PM
timesize
| Ytd | 73.28% | |
| 1y | -79.28% |
2.00
day range
2.23
1.06
52 week range
9.98
| Open | 2.22 | Prev Close | 2.18 | Low | 2.00 | High | 2.23 | Mkt Cap | 15.16M |
| Vol | 92.71K | Avg Vol | 123.40K | EPS | -3.79 | P/E | N/A | Forward P/E | -0.49 |
| Beta | 0.90 | Short Ratio | 0.15 | Inst. Own | 9.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 1.61 | 200-d Avg | 1.52 | 1yr Est | 5.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-10 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-13 | 2024-09 | 0 | -0.7 | N/A | N/A |
| 2024-09-30 | 2024-06 | 0 | -6.6 | N/A | N/A |
| 2024-05-14 | 2024-03 | 0 | -2 | N/A | N/A |
| 2024-02-12 | 2023-12 | -3.2 | -2.2 | 1 | 31.25% |
| 2023-11-08 | 2023-09 | 0 | -2.9 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-07-01 | ThinkEquity | Upgrade | Buy | |
| 2023-11-30 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2023-08-22 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2023-07-18 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2023-05-17 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2023-05-17 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-08 | BERMAN RICHARD JAY | Director | 69.24K | Stock Award(Grant) |
| 2024-06-23 | DO CUONG VIET | Chief Executive Officer | 0.00 | Stock Award(Grant) |
| 2023-11-30 | GORLIN STEVEN | Director | 46.36K | Sale |
| 2023-11-08 | HARIRI ROBERT J | Director | 42.25K | Stock Award(Grant) |
| 2024-06-23 | KIM JOANNE WENDY | Chief Financial Officer | 93.94K | Stock Award(Grant) |
| 2024-06-23 | PALUMBO JOSEPH M | Officer | 119.20K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 56.84K | 122.20K | 0.32% |
| 2024-09-29 | Geode Capital Management, LLC | 38.17K | 82.07K | 0.21% |
| 2024-09-29 | Zullo Investment Group, Inc. | 25.00K | 53.75K | 0.14% |
| 2024-09-29 | Cerity Partners LLC | 17.23K | 37.04K | 0.10% |
| 2024-09-29 | United Capital Management of KS, Inc. | 10.00K | 21.50K | 0.06% |
| 2024-09-29 | National Bank of Canada/FI | 4.30K | 9.24K | 0.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 41.51K | 89.24K | 0.23% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 21.82K | 46.90K | 0.12% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 14.76K | 31.74K | 0.08% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 5.16K | 11.09K | 0.03% |
| 2024-10-30 | Fidelity Total Market Index Fund | 1.86K | 3.99K | 0.01% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 2.30K | 4.93K | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2025-07-07 |
| 1 : 10 | 2024-08-06 |
| 2 : 250 | 2019-11-22 |
| 2 : 250 | 2019-11-08 |
| 2 : 250 | 2019-08-13 |